Ascendis Pharma AS (NAS:ASND)
$ 137.5 -2.81 (-2%) Market Cap: 8.39 Bil Enterprise Value: 8.62 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 71/100

Q4 2023 Ascendis Pharma A/S Earnings Call Transcript

Feb 07, 2024 / 09:30PM GMT
Release Date Price: $139.29 (-1.10%)
Operator

Good day, and thank you for standing by. Welcome to the fourth quarter 2023 Ascendis Pharma earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Tim Lee, Senior Director of Investor Relations. Please go ahead.

Tim Lee;S;Senior Director of IR
Ascendis Pharma A

/-

Thank you, operator, and thank everyone for joining our full-year 2023 financial results conference call. I'm Tim Lee, Senior Director of Investor Relations at Ascendis Pharma. Joining me on the call today are Jan Mikkelsen, President and Chief Executive Officer; Scott Smith, Executive Vice President and Chief Financial Officer; Dr. Stina Singel, Executive Vice President and Head of Clinical Development, Oncology; and Joe Kelly, Senior Vice President, Head of US Commercial, Endocrinology.

Before we begin, I'd like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot